Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Via Ritzau
via.ritzau.dk > pressemeddelelse > 15/12/5575 > xyra-llc

Xyra, LLC | Globenewswire

2+ week, 8+ hour ago   (183+ words) XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation LOS ALTOS, California, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Open-label, dose-escalation study using cardiac rhythm data from implantable and wearable AF monitors allows…...

Via Ritzau
via.ritzau.dk > pressemeddelelse > 15/11/5177 > 4basebio

4basebio | Globenewswire

2+ week, 5+ day ago   (261+ words) Through the collaboration, Genezen will offer access to 4basebio’s synthetic DNA developed specifically for viral vector applications, creating a more streamlined path for cell and gene therapy developers to advance programs toward the clinic. The cell-free manufacturing approach can also…...